Trial Profile
An open label study to investigate the safety and tolerability of GK Activator (2) in patients with type 2 diabetes mellitus not adequately controlled with glimepiride as a standard prescribed therapy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2010
Price :
$35
*
At a glance
- Drugs Piragliatin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 23 Feb 2010 Actual initiation date (Aug 2006) added as reported by Roche.
- 08 Jan 2008 New trial record.